A neuroinflamação da Doença de Alzheimer e sua correlação anatômica
DOI:
https://doi.org/10.34119/bjhrv6n1-133Keywords:
hipocampo, Alzheimer, neuroinflamaçãoAbstract
A doença de Alzheimer (DA) é uma patologia neurodegenerativa crônica e irreversível, marcada principalmente pela perda de memória e seu comprometimento cognitivo progressivo. Suas complicações decorrem, principalmente, em virtude de um processo neuroinflamatório associado à reposta de micróglias e astrócitos à deposição de placas β-amiloides e ao emaranhamento de proteínas tau. Ainda assim, diversas hipóteses de base molecular divergem sobre a causa exata da DA. Sabe-se, porém, que essa patologia não é limitada à níveis celulares, mas também possui repercussões na anatomia cerebral. Segmentos distintos são afetados com base no estágio da doença e entender a relação da anatomia com a DA é de grande importância para auxílio diagnóstico e tratamento. Nesse sentido, na presente revisão, buscou-se evidenciar as alterações anatômicas em cérebros com neuroinflamação decorrente da doença de Alzheimer, bem como associações com a sintomatologia observada.
References
Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer’s disease. Lancet. 30 de julho de 2016;388(10043):505–17.
Bondi MW, Edmonds EC, Salmon DP. Alzheimer’s Disease: Past, Present, and Future. J Int Neuropsychol Soc. outubro de 2017;23(9–10):818–31.
Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci. 7 de setembro de 2011;12(10):585–601.
Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. março de 1999;45(3):358–68.
Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 27 de junho de 2006;66(12):1837–44.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
Whitwell JL, Dickson DW, Murray ME, Weigand SD, Tosakulwong N, Senjem ML, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: a case-control study. The Lancet Neurology [Internet]. 1o de outubro de 2012;11(10):868–77. Disponível em: https://www.sciencedirect.com/science/article/pii/S1474442212702004
Onyango IG, Jauregui GV, Čarná M, Bennett JPJ, Stokin GB. Neuroinflammation in Alzheimer’s Disease. Biomedicines. 7 de maio de 2021;9(5).
Holmes C. Review: Systemic inflammation and Alzheimer’s disease. Neuropathology and Applied Neurobiology [Internet]. 1o de fevereiro de 2013 [citado 13 de dezembro de 2022];39(1):51–68. Disponível em: https://doi.org/10.1111/j.1365-2990.2012.01307.x
Businaro R, Corsi M, Asprino R, Di Lorenzo C, Laskin D, Corbo RM, et al. Modulation of Inflammation as a Way of Delaying Alzheimer’s Disease Progression: The Diet’s Role. Curr Alzheimer Res. 22 de fevereiro de 2018;15(4):363–80.
Iulita MF, Ganesh A, Pentz R, Flores Aguilar L, Gubert P, Ducatenzeiler A, et al. Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. Journal of Alzheimer’s Disease. 2019;67(1):327–41.
Cuello AC. Early and Late CNS Inflammation in Alzheimer’s Disease: Two Extremes of a Continuum? Trends in Pharmacological Sciences [Internet]. 1o de novembro de 2017 [citado 10 de dezembro de 2022];38(11):956–66. Disponível em: https://doi.org/10.1016/j.tips.2017.07.005
Rogers J. Principles for central nervous system inflammation research: A call for a consortium approach. Alzheimer’s & Dementia [Internet]. 1o de novembro de 2018 [citado 10 de dezembro de 2022];14(11):1553–9. Disponível em: https://doi.org/10.1016/j.jalz.2018.01.008
Nordengen K, Kirsebom BE, Henjum K, Selnes P, Gísladóttir B, Wettergreen M, et al. Glial activation and inflammation along the Alzheimer’s disease continuum. Journal of Neuroinflammation [Internet]. 21 de fevereiro de 2019;16(1):46. Disponível em: https://doi.org/10.1186/s12974-019-1399-2
Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer’s disease trajectory. Brain [Internet]. 1o de março de 2017 [citado 12 de novembro de 2022];140(3):792–803. Disponível em: https://doi.org/10.1093/brain/aww349
Edison P, Brooks DJ. Role of Neuroinflammation in the Trajectory of Alzheimer’s Disease and in vivo Quantification Using PET. Journal of Alzheimer’s Disease. 2018;64(s1):S339–51.
Parbo P, Ismail R, Hansen KV, Amidi A, Mårup FH, Gottrup H, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain [Internet]. 1o de julho de 2017 [citado 12 de novembro de 2022];140(7):2002–11. Disponível em: https://doi.org/10.1093/brain/awx120
Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature [Internet]. 1o de dezembro de 2017;552(7685):355–61. Disponível em: https://doi.org/10.1038/nature25158
Ledo JH, Azevedo EP, Beckman D, Ribeiro FC, Santos LE, Razolli DS, et al. Cross Talk Between Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by Alzheimer’s Amyloid-β Oligomers in Mice. J Neurosci. 30 de novembro de 2016;36(48):12106–16.
Rodríguez-Giraldo M, González-Reyes RE, Ramírez-Guerrero S, Bonilla-Trilleras CE, Guardo-Maya S, Nava-Mesa MO. Astrocytes as a Therapeutic Target in Alzheimer’s Disease-Comprehensive Review and Recent Developments. Int J Mol Sci. 7 de novembro de 2022;23(21).
Medeiros R, LaFerla FM. Astrocytes: Conductors of the Alzheimer disease neuroinflammatory symphony. Experimental Neurology [Internet]. 1o de janeiro de 2013;239:133–8. Disponível em: https://www.sciencedirect.com/science/article/pii/S0014488612003901
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature [Internet]. 1o de janeiro de 2017;541(7638):481–7. Disponível em: https://doi.org/10.1038/nature21029
Hampel H, Caraci F, Cuello AC, Caruso G, Nisticò R, Corbo M, et al. A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer’s Disease. Front Immunol. 2020;11:456.
Bartus RT, Dean RL, Beer B, Lippa AS. The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science [Internet]. 30 de julho de 1982 [citado 13 de dezembro de 2022];217(4558):408–14. Disponível em: https://doi.org/10.1126/science.7046051
Hampel H, Mesulam MM, Cuello AC, Khachaturian AS, Vergallo A, Farlow MR, et al. Revisiting the Cholinergic Hypothesis in Alzheimer’s Disease: Emerging Evidence from Translational and Clinical Research. J Prev Alzheimers Dis. 2019;6(1):2–15.
Lewis Phillip Rowland, Hiram Houston Merritt Junior, Cláudia Lúcia Caetano de Araújo FDM. Merritt Tratado de Neurologia. Em p. 884.
Rai S, Kamat PK, Nath C, Shukla R. A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats. J Neuroimmunol. 15 de janeiro de 2013;254(1–2):1–9.
Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C, et al. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer’s Disease: Understanding the Therapeutics Strategies. Mol Neurobiol. janeiro de 2016;53(1):648–61.
Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease. Ageing Res Rev. julho de 2021;68:101339.
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 10 de abril de 1992;256(5054):184–5.
Soreghan B, Kosmoski J, Glabe C. Surfactant properties of Alzheimer’s A beta peptides and the mechanism of amyloid aggregation. J Biol Chem. 18 de novembro de 1994;269(46):28551–4.
Meraz-Ríos MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernández J, Campos-Peña V. Inflammatory process in Alzheimer’s Disease. Front Integr Neurosci. 2013;7:59.
McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. setembro de 1995;21(2):195–218.
Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, et al. Inflammation and Alzheimer’s disease pathogenesis. Neurobiol Aging. outubro de 1996;17(5):681–6.
Beyreuther K, Multhaup G, Masters CL. Alzheimer’s Disease: Genesis of Amyloid. Em: Ciba Foundation Symposium 199 ‐ The Nature and Origin of Amyloid Fibrils [Internet]. 2007 [citado 13 de dezembro de 2022]. p. 119–31. (Novartis Foundation Symposia). Disponível em: https://doi.org/10.1002/9780470514924.ch8
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 26 de maio de 1998;95(11):6448–53.
Lei P, Ayton S, Bush AI. The essential elements of Alzheimer’s disease. J Biol Chem. junho de 2021;296:100105.
Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, et al. Elevated cortical zinc in Alzheimer disease. Neurology. 11 de julho de 2006;67(1):69–75.
James SA, Volitakis I, Adlard PA, Duce JA, Masters CL, Cherny RA, et al. Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. Free Radic Biol Med. 15 de janeiro de 2012;52(2):298–302.
Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A. 2 de setembro de 1997;94(18):9866–8.
Iqbal K, Wiśniewski HM, Shelanski ML, Brostoff S, Liwnicz BH, Terry RD. Protein changes in senile dementia. Brain Res. 6 de setembro de 1974;77(2):337–43.
Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. maio de 1975;72(5):1858–62.
Lee G, Neve RL, Kosik KS. The microtubule binding domain of tau protein. Neuron. junho de 1989;2(6):1615–24.
Bracco PA, Gregg EW, Rolka DB, Schmidt MI, Barreto SM, Lotufo PA, et al. Lifetime risk of developing diabetes and years of life lost among those with diabetes in Brazil. J Glob Health. 2021;11:04041.
Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nature Reviews Drug Discovery [Internet]. 1o de junho de 2007;6(6):464–79. Disponível em: https://doi.org/10.1038/nrd2111
Köpke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem. 15 de novembro de 1993;268(32):24374–84.
Roy S, Zhang B, Lee VMY, Trojanowski JQ. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. janeiro de 2005;109(1):5–13.
Acosta C, Anderson HD, Anderson CM. Astrocyte dysfunction in Alzheimer disease. Journal of Neuroscience Research [Internet]. 1o de dezembro de 2017 [citado 11 de dezembro de 2022];95(12):2430–47. Disponível em: https://doi.org/10.1002/jnr.24075
Machado A, Machado Hartel L. Neuroanatomia Funcional. 3o ed. Atheneu;
S. Smell R. Neuroanatomia Clínica. 7o ed. Wolters Kluwer;
Purves D, Augustine G, Fitzpatrick D, C. Hall W, Lamantia AS, O. Mcnamara J, et al. Neuroscience. 3o ed. Sunderland, Massachusetts U.S.A: Sinauer Associates;
Netter FH. Netter Anatomia Humana. 7o ed. Rio de Janeiro: Elsevier; 2019.
Scott SA, DeKosky ST, Scheff SW. Volumetric atrophy of the amygdala in Alzheimer’s disease. Neurology [Internet]. 1o de março de 1991;41(3):351. Disponível em: http://n.neurology.org/content/41/3/351.abstract
Scott SA, Sparks DL, Scheff SW, Dekosky ST, Knox CA. Amygdala cell loss and atrophy in Alzheimer’s disease. Annals of Neurology [Internet]. 1o de outubro de 1992 [citado 13 de dezembro de 2022];32(4):555–63. Disponível em: https://doi.org/10.1002/ana.410320412
Molinuevo JL, Ripolles P, Simó M, Lladó A, Olives J, Balasa M, et al. White matter changes in preclinical Alzheimer’s disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels. Neurobiology of Aging [Internet]. 1o de dezembro de 2014;35(12):2671–80. Disponível em: https://www.sciencedirect.com/science/article/pii/S0197458014003935
Talmelli LF da S, Vale F de AC do, Gratão ACM, Kusumota L, Rodrigues RAP. Doença de Alzheimer: declínio funcional e estágio da demência. Acta Paulista de Enfermagem [Internet]. 2013;26(3):219–25. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-21002013000300003&lang=pt
Gallucci Neto J, Tamelini MG, Forlenza OV. Diagnóstico diferencial das demências. Archives of Clinical Psychiatry (São Paulo) [Internet]. junho de 2005;32(3):119–30. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-60832005000300004&lang=pt
Banks WA. Developing drugs that can cross the blood-brain barrier: applications to Alzheimer’s disease. BMC Neurosci. 10 de dezembro de 2008;9 Suppl 3(Suppl 3):S2.
Tosun D, Landau S, Aisen PS, Petersen RC, Mintun M, Jagust W, et al. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals. Brain. 1o de maio de 2017;140(5):1499–512.
Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold Amyloid Predicts Tau Deposition in Aging. J Neurosci. 9 de maio de 2018;38(19):4482–9.
Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K, et al. Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. J Neurosci. 17 de janeiro de 2018;38(3):530–43.
Ramos LR, Montaño MB. Doença de Alzheimer. Revista Brasileira de Medicina. 2001;58(SPEC. ISS.):33–9.
Schafer DP, Lehrman EK, Stevens B. The “quad-partite” synapse: Microglia-synapse interactions in the developing and mature CNS. Glia [Internet]. 1o de janeiro de 2013 [citado 17 de dezembro de 2022];61(1):24–36. Disponível em: https://doi.org/10.1002/glia.22389
Montero-Crespo M, Domínguez-Álvaro M, Alonso-Nanclares L, DeFelipe J, Blazquez-Llorca L. Three-dimensional analysis of synaptic organization in the hippocampal CA1 field in Alzheimer’s disease. Brain [Internet]. 1o de fevereiro de 2021 [citado 17 de dezembro de 2022];144(2):553–73. Disponível em: https://doi.org/10.1093/brain/awaa406
Neto MJ, Cabral CRL, Soares JO, Pontes NA. O comportamento do idoso com Alzheimer sob a ótica do discente de enfermagem: relato de experiência. Brazilian Journal of Development. DOI:10.34117/bjdv8n12-140. 2022.
Nascimento AB, Vieira NC, Moreira AC, Magalhães FE, Oliveira MS, Liberato MC, Neto AE. Benzofenona Prenilada como candidata no tratamento do mal de Alzheimer: uma abordagem in sílico. Brazilian Journal of Development. DOI:10.34117/bjdv8n12-063. 2022.
